RxDoctor Payments Data

Tonya Hatfield

Acute Care · Lexington, KYNPI 1386839272

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,699 of the $2,306 with a category attached, or 73.7%. 6 manufacturers reported payments, led by Abbott at 46.4% of the total. 2025 is the largest year on record at $1,171, 4.5 times the $261 reported in 2021.

$2,306in general payments, 2019–2025

Across 47 payments — averaging $49.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$982
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$173
  • Pacira Pharmaceuticals Incorporated$35
  • AbbVie$31
  • AstraZeneca$16

What the payments were for

  • Travel & lodging$60726%
  • Food & beverage$1,69974%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,306 in reported general payments places this provider in the 85th percentile of 319 acute care providers in Kentucky.

See all acute care providers in Kentucky

Medicare billing

Part B allowed, 2024
$14,734
Medicare patients
29
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$16,794
JardianceEmpagliflozin13$13,665
EntrestoSacubitril/Valsartan18$11,897
FarxigaDapagliflozin Propanediol13$7,191
Amiodarone Hcl19$562
Bumetanide12$471
Torsemide22$317
Potassium Chloride20$257
Pantoprazole Sodium18$227
Spironolactone19$92
Atorvastatin Calcium14$91
Warfarin Sodium17$77
Allopurinol18$75
Hydralazine Hcl13$66
Metoprolol Succinate14$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$16$7,19113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 319 acute care providers in Kentucky.

Other acute care in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →